Patheon Acquires Roche API Site
PTSM: Pharmaceutical Technology Sourcing and Management
Patheon adds API manufacturing capacity with acquisition of Roche’s Florence, SC facility.
Patheon has signed an agreement to acquire an API manufacturing facility in Florence, SC, from Roche Holdings, Inc., which will provide Patheon with a major US API operation capable of supporting products from clinical scale to commercial manufacturing, according to a Nov. 28, 2016 press statement.
Patheon will acquire the 1,100-acre, 300,000 square-foot facility with manufacturing capacity for API ranging from development to manufacturing services. The acquisition expands the company’s capacity for manufacturing highly potent compounds and adds capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying, the company reports.
According to the announcement, Patheon will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. The company also announced a multi-year supply arrangement with Roche, which Patheon expects will help defray the costs associated with running the site for the next few years while it adds new client work into the facility.
The site features reactors ranging from 50–11,000 liters producing multiple products simultaneously, and is compliant with applicable regulations, such as cGMP, safety, and environmental standards.
Soucre: Patheon
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
